Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy.

Benjamin SchulteMaximilian WübboldingFiona MarraKerstin PortMichael P MannsDavid BackMarkus CornbergDirk O StichtenothChristoph Höner Zu SiederdissenBenjamin Maasoumy

Published in: Open forum infectious diseases (2020)

DDIs during antiviral treatment still affect about 40% of HCV patients. The lower DDI potential of modern DAA regimens is partly counteracted by changing patient characteristics. Therefore, DDIs should not be underestimated.

Keyphrases

hepatitis c virus
end stage renal disease
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
case report
stem cells
emergency department
bone marrow
risk assessment
combination therapy
climate change
patient reported
electronic health record